Drug/Small Molecule:
homatropine methylbromide

PharmGKB contains no dosing guidelines for this drug/small molecule. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this drug/small molecule. If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?
2D structure from PubChem
provided by PubChem

Overview

Generic Names
Trade Names
  • Arkitropin
  • Camatropine
  • DL-Homatropine methyl bromide
  • DL-Methylbromide
  • Esopin
  • Homapin
  • Homatromide
  • Homatropine methyl bromide
  • Humulon lead salt
  • Hycodan, probilagol
  • Malcotran
  • Mesopin
  • Methyl Bromide Homatropine
  • Methylhomatropine
  • Methylhomatropine bromide
  • Novatrin
  • Novatrine
  • Novatropine
  • Npvatropine
  • Sed-tems
  • Sethyl
  • Tropinium methobromide mandelate
Brand Mixture Names
  • Acidobyl & Cascara (Bile Salts + Casanthranol + Dehydrocholic Acid + Docusate Sodium + Homatropine Methylbromide)
  • Acidobyl (Bile Salts + Dehydrocholic Acid + Docusate Sodium + Homatropine Methylbromide)
  • Debiline H (Deoxycholic Acid + Homatropine Methylbromide + Pepsin)

PharmGKB Accession Id:
PA164749405

Description

Homatropine methylbromide is a quaternary ammonium muscarinic acetylcholine receptor antagonist belonging to the group of medicines called anti-muscarinics. Homatropine is used to treat duodenal or stomach ulcers or intestine problems. It can be used together with antacids or other medicine in the treatment of peptic ulcer. It may also be used to prevent nausea, vomiting, and motion sickness.

Source: Drug Bank

Indication

Used in conjunction with antacids or histamine H2-receptor antagonists in the treatment of peptic ulcers, gastric ulcers and duodenal ulcers, to reduce further gastric acid secretion and delay gastric emptying.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Homatropine is a quaternary ammonium muscarinic acetylcholine receptor antagonist. The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Homatropine methylbromide inhibits the muscarinic actions of acetylcholine on structures innervated by postganglionic cholinergic nerves as well as on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These postganglionic receptor sites are present in the autonomic effector cells of the smooth muscle, cardiac muscle, sinoatrial and atrioventricular nodes, and exocrine glands. Depending on the dose, anticholinergics may reduce the motility and secretory activity of the gastrointestinal system, and the tone of the ureter and urinary bladder and may have a slight relaxant action on the bile ducts and gallbladder.

Source: Drug Bank

Pharmacology

Homatropine methylbromide belongs to the group of medicines called anti-muscarinics. Homatropine is used to treat duodenal or stomach ulcers or intestine problems. It can be used together with antacids or other medicine in the treatment of peptic ulcer. It may also be used to prevent nausea, vomiting, and motion sickness.

Source: Drug Bank

Chemical Properties

Chemical Formula

C17H24BrNO3

Source: Drug Bank

Isomeric SMILES

C[N+]1([C@@H]2CC[C@H]1C[C@H](C2)OC(=O)[C@H](C3=CC=CC=C3)O)C.[Br-]

Source: Drug Bank

[Br-].[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)C1=CC=CC=C1)[N+]2(C)C

Source: Drug Bank

Canonical SMILES

[Br-].C[N+]

Source: Drug Bank

Average Molecular Weight

370.281

Source: Drug Bank

Monoisotopic Molecular Weight

369.093956286

Source: Drug Bank

LinkOuts

Web Resource:
Wikipedia
DrugBank:
DB00725
ChEBI:
50373
KEGG Drug:
D02070
PubChem Compound:
6646
PubChem Substance:
149623
Drugs Product Database (DPD):
86681
Therapeutic Targets Database:
DAP000823

Clinical Trials

These are trials that mention homatropine methylbromide and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.